Which drugs may be hit with ne­go­ti­a­tions if the rec­on­cil­i­a­tion bill pass­es? Wall St. an­a­lysts ex­plain

Be­yond the back and forth of whether De­moc­rats’ drug price ne­go­ti­a­tion plan is nec­es­sary to bring down costs, or just a thin­ly veiled at­tempt at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA